I was recently on a panel discussion on New Hampshire Public Radio’s program The Exchange, along with Dr. Robert Santulli, Associate Professor of Psychiatry at Dartmouth, Director of the Dartmouth…

It is always disappointing when a clinical trial is stopped prematurely either because of serious side effects or because the treatment is deemed to be ineffective. However, science moves forward from both successful and unsuccessful findings, and, in the case of Alzheimer’s disease treatment, we are finding that treatments will likely be more successful when they are targeted to specific patient groups, such as matching a form of treatment with the appropriate stage of disease.